The expression of matrix metalloproteinases in intrahepatic cholangiocarcinoma, hilar (Klatskin tumor), middle and distal extrahepatic cholangiocarcinoma, gallbladder cancer, and ampullary carcinoma: Role of matrix metalloproteinases in tumor progression and prognosis

Turkish Journal of Gastroenterology

Volumn 20, Issue 1, 2009, Pages 41-47

  Kirimlioǧlu, Hale ^a,b   Türkmen, Ilknur ^a   Başsüllü, Nuray ^a   Dirican, Abuzer ^a   Karadaǧ, Neşe ^a   Kirimlioǧlu, Vedat ^a  

^a INONU UNIVERSITY   (Turkey)

^b Turgut Özal Tip Merkesi Genel Cerrahi A D   (Turkey)

Author keywords

Biliary neoplasms; Immunohistochemistry; Matrix metalloproteinases

Indexed keywords

GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE 14;

ARTICLE; BILE DUCT CARCINOMA; CANCER INVASION; CANCER LOCALIZATION; CARCINOGENESIS; CONTROLLED STUDY; DISTANT METASTASIS; DYSPLASIA; ENZYME ANALYSIS; EPITHELIUM TUMOR; EXTRAHEPATIC CHOLANGIOCARCINOMA; GALLBLADDER CANCER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRAHEPATIC CHOLANGIOCARCINOMA; KLATSKIN TUMOR; LYMPH NODE METASTASIS; METAPLASIA; PERINEURIUM; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR DIFFERENTIATION; TUMOR GROWTH; TUMOR LOCALIZATION; VATER PAPILLA CARCINOMA;

ADENOCARCINOMA; AMPULLA OF VATER; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; DISEASE PROGRESSION; GALLBLADDER NEOPLASMS; HEPATIC DUCT, COMMON; HUMANS; IMMUNOHISTOCHEMISTRY; KLATSKIN'S TUMOR; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; NEOPLASM INVASIVENESS; PROGNOSIS;

EID: 63449130951     PISSN: 13004948     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Powell WC, Knox JD, Navre M, et al. Expression of the me-talloproteinase matrilysin in DU-145 cells increases their invasive potential in severe combined immunodeficient mice. Cancer Res 1993; 53: 417-22.
2. Shaib Y, El-Serag HB. The epidemiology of cholangiocarci- noma. Semin Liver Dis 2004; 24: 115-25.
3. Kang YK, Kim WH, Lee HW, et al. Mutation of p53 and K- ras, and loss of heterozygosity of APC in intrahepatic cho- langiocarcinoma. Lab Invest 1999; 79: 477-83.
4. Rashid A. Cellular and molecular biology of biliary tract cancers. Surg Oncol Clin North Am 2002; 11: 995-1009.
5. Yang B, House MG, Guo M, et al. Promoter methylation profiles of tumor suppressor genes in intrahepatic and extrahepatic cholangiocarcinoma. Mod Pathol 2005; 18: 412-20.
6. Sherr CJ. Cancer cell cycles. Science 1996; 274: 1672-7.
7. MacFaul GR, Chapman RW. Sclerosing cholangitis. Curr Opin Gastroenterol 2005; 21: 348-53.
8. Patel T. Increasing incidence and mortality of primary in-trahepatic cholangiocarcinoma in the United States. Hepatology 2001; 33: 1353-7.
9. Jarnagin WR, Ruo L, Little SA, et al. Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer 2003; 98: 1689-700.
10. Wu YI, Munshi HG, Snipas SJ, et al. Activation-coupled membrane-type 1 matrix metalloproteinase membrane trafficking. Biochem J 2007; 407: 171-7.
11. Chiba H, Nagai H, Ohdaira T, et al. Immunohistochemical study of characteristics of bile duct dysplasia evaluated on the basis of expression of metastasis/invasion-related factors and p53. J Hepatobiliary Pancreat Surg 2004; 11: 409-16.
12. Bergers G, Brekken R, McMahon G, et al. Matrix metallop-roteinase-9 triggers the angiogenic switch during carcino-genesis. Nature Cell Biol 2000; 2: 737-44.
13. Fan YZ, Zhang JT, Yang HC, et al. Expression of MMP-2, TIMP-2 protein and the ratio of MMP-2/TIMP-2 in gallbladder carcinoma and their significance. World J Gastro- enterol 2002; 8: 1138-43.
14. Jo Chae K, Rha SY, Oh BK, et al. Expression of matrix me- talloproteinase-2 and -9 and tissue inhibitor of metallopro- teinase-1 and -2 in intraductal and nonintraductal growth type of cholangiocarcinoma. Am J Gastroenterol 2004; 99: 68-75.
15. Miwa S, Miyagawa S, Soeda J, et al. Matrix metalloprote- inase-7 expression and biologic aggressiveness of cholangi- ocellular carcinoma. Cancer 2002; 94: 428-34.
16. Shirabe K, Shimada M, Kajiyama K, et al. Expression of matrix metalloproteinase-9 in surgically resected intrahe- patic cholangiocarcinoma. Surgery 1999; 126: 842-6.
17. Terada T, Okada Y, Nakanuma Y. Expression of immuno- reactive matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in human normal livers and primary liver tumors. Hepatology 1996; 23: 1341-4.
18. Jan YY, Yeh TS, Yeh JN, et al. Expression of epidermal growth factor receptor, apomucins, matrix metalloprote- inases, and p53 in rat and human cholangiocarcinoma: appraisal of an animal model of cholangiocarcinoma. Ann Surg 2004; 240: 89-94.